
Preliminary data from a crucial trial concerning a Novo Nordisk obesity drug may accelerate sales in 2023, according to Danish newspaper Børsen in reference to an analysis from Danish bank and financial analyst Nordea.
The growth escalation in Novo Nordisk's obesity drug sales may actually become a factor some years earlier than what both Novo Nordisk and the stock market have expected.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app